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Abstract: Hepatitis B is a widespread disease which affects millions of people worldwide. Chronic
hepatitis B (CHB) can lead to significant morbidity and mortality due to complications such as cirrhosis
and hepatocellular carcinoma. The pathophysiology of hepatitis is critical to diagnosing CHB. Deciding
which patients with CHB should be treated is an important decision as treatment can often lead to better
outcomes in the appropriate patient population. The nucleos(t)ide analog inhibitors entecavir and tenofovir
are currently the mainstay of treatment as they are able to successfully suppress the virus and lead to fewer
complications. Novel therapies are currently being developed which may offer a potential cure for this
disease in the future.
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Introduction
Hepatitis B infection is a common cause of chronic liver
disease. The World Health Organization (WHO) estimates
that 257 million people are living with hepatitis B (1).
In 2015, over 800,000 deaths worldwide were attributed
to complications of hepatitis B infection; the majority of
which were related to complications of chronic infection
such as the development of cirrhosis and hepatocellular
carcinoma (HCC) (1). The significant morbidity and
mortality associated with chronic hepatitis B (CHB) has led
to a flurry of research and advances in understanding the
pathophysiology and natural history of the infection. This
knowledge has led to development of novel therapies for
treatment. This article is aimed at reviewing characteristics
of HBV, its impact on development of HCC, the criteria
for treatment of CHB, and current first-line and future
therapies.
HBV characteristics
The hepatitis B virus (HBV) is composed of a partially
d o u b l e- s t r a n d e d D N A g e n o m e p a c k a g e d w i t h a n
HBV polymerase (2). The genome is covered by a
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protein capsid, the so-called hepatitis B core antigen
(HBcAg), which is then enclosed in a lipid bilayer that
contains surface proteins, the hepatitis B surface antigen
(HBsAg) (2). The HBsAg assists the virus particle in
gaining entry into hepatocytes (2). Once the virus infects
a hepatocyte, the partially double-stranded DNA is
transformed into a stable circular form called covalently
closed circular DNA (cccDNA) (3). The cccDNA is very
stable and a difficult to eradicate form of the HBV genome
that resides in the hepatocyte for the life of the cell (3).
Replication of the virus consists of transcription of the
cccDNA into pre-genomic RNA that is reverse transcribed
to HBV DNA before being packaged into another viral
particle (4).
Several key areas of the HBV genome with clinical
relevance beyond viral assembly are the core and precore
regions. These regions are involved in assembly of the
HBcAg and the Hepatitis B e-antigen (HBeAg) (3). The
precore region is transcribed into precore mRNA that is
translated into a single peptide, which is than cleaved to
form HBeAg (2). The function of HBeAg is still not well
defined but mutations involving the precore region are
associated with the development of HBeAg-negative chronic
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Table 1 CHB serologic interpretation
Variables

HBsAg

HBeAg

HBV DNA

Anti-HBe

Inactive CHB**

+

–

–

+

HBeAg-positive CHB*

+

+

+/++

–

HBeAg-negative CHB*

+

–

+/++

+

Immune-tolerant CHB**

+

+

+++

–

Immune-active CHB***

+

+/–

++/+++

+/–

*, serum ALT levels can fluctuate from normal to abnormal; **, serum ALT levels are normal in these cases; ***, serum ALT levels are
elevated.

hepatitis B (5,6). There is also an increased likelihood of
seroconversion of HBeAg or going from HBeAg positive
to HBeAg negative with anti-HBe (5,6). Despite increased
rates of seroconversion and lower levels of viremia,
HBeAg-negative hepatitis B with precore mutations is
associated with older individuals and more advanced liver
disease (7). The core region is also associated with advanced
liver disease, as well as an increased risk of HCC, but
mutations in the core region are not as firmly correlated with
HBeAg-negative HBV as precore mutations (8,9). Identifying
variants of the core and precore regions is not standard
practice when evaluating which patients require treatment;
however, it can be useful in stratifying patients who are at
highest risk of progression of CHB to cirrhosis (10).
In addition to the mutations in the core/precore regions
of the HBV genome, there are many different genotypes
of HBV, and several subtypes within each genotype (11).
These genotypes are lettered from A to J and generally
have a unique geographical distribution (11). Similar to the
precore/core mutations, the clinical utility of identifying
the HBV genotype can provide further information on
the risk of disease progression and development of HCC
(10,11). For example, genotype B has been associated with a
milder form of chronic hepatitis B with slower progression
of disease and a higher likelihood of HBeAg seroconversion
when compared with genotype C (12). Genotype testing
is not yet standard of care but can help guide treatment
considerations and monitoring for CHB.
Diagnosis of HBV infection
Serological markers are the primary method by which
infection with HBV is diagnosed. The presence of HBsAg
is diagnostic of infection and if present for more than
6 months is indicative of chronic infection. Multiple phases
of CHB have been identified, each with its own treatment
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implications (10,13,14). These are listed in Table 1.
Screening for HBV is recommended in areas where
prevalence is considered high (>2% prevalence) (4). The
risk of developing CHB varies by age with infants less than
1 year of age having a >80% chance of developing CHB
whereas toddlers between 1 and 6 years have between a
30–50% risk (1). Less than 5% of adults with an acute
infection will develop CHB but close to a third of these
patients who acquire CHB will develop advanced liver
disease and/or HCC (1).
Risk factors for progression of HBV chronic liver
disease
Several risk factors for progression of CHB to cirrhosis
have been identified. HBV DNA level in blood, specifically
a level >104 copies/mL, was one of the strongest predictors
of progression to cirrhosis (15). This was independent of
ALT, HBeAg status, age, and other factors (15). Older age is
also a strong predictor of progression, but this is more likely
due longer duration of disease rather than an independent
risk factor (16). Another commonly associated risk factor
is male sex although the exact mechanism is not well
understood (16).
The overall incidence of cirrhosis in patients with HBeAgpositive hepatitis B was 1.6 and 3.8 per 100 person-years
in East Asian and European countries, respectively (16). In
patients with HBeAg-negative chronic hepatitis B the
incidence was 2.8 and 9.7 for the same East Asian and
European countries, respectively (16). The incidence in
per 100 person-years roughly corresponds to a 5-year
cumulative incidence of 8% and 17% in the HBeAgpositive CHB compared to a 5-year incidence of 13% and
38% in HBeAg-negative CHB in East Asian and European
countries, respectively (16). While this seems to indicate
that HBeAg-negative CHB is a risk factor for progression to
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cirrhosis, this is also likely related to duration of disease (16).
Other risk factors associated with increased progression to
cirrhosis include HBV genotype, presence of co-infections of
hepatitis C or hepatitis D, and presence of other chronic liver
diseases such as non-alcohol steatohepatitis (NASH) (16).
Liver cancer and HBV
HBV is the most common cause of HCC, being responsible
for >50% of cases worldwide (17). The relative risk of
developing HCC increases by 15–20-fold in patients with
HBV compared to uninfected patients (18) with an annual
incidence of HCC in hepatitis B carriers of 0.5% (19,20). It
is thought that 10–16% of patients with HCC in the US are
infected with HBV (21).
HBV is unique in that patients with the disease are at
increased risk of developing HCC, even in the absence
of cirrhosis. This is in contrast to chronic hepatitis C and
other causes of liver disease where cirrhosis is a prerequisite
to the development of HCC. The pathogenesis of HBV is
distinctive because HBV initiates hepatic carcinogenesis
by gaining entry into hepatocytes leading to integration
into the host genome with subsequent alteration of the
host DNA/RNA (22). This can cause structural alterations,
sequence variations, deletions and inhibition of tumor
suppressor genes leading to the development of cancer
(23-26). Of note, Liu et al. showed risk factors for
development of HCC in the setting of HBV in the absence
of cirrhosis was associated with male gender and higher
viral loads (27). HBV genotype also appears to play a role
as studies have shown that genotype C and F CHB patients
are more likely to develop HCC when compared to other
genotypes (28,29). In addition, the basal core promoter
T1762/A1764 mutation has been directly linked to the
development of HCC (27).
Due to this increased risk of developing HCC, certain
patient populations infected with HBV should undergo
surveillance for HCC. Screening options include regular
blood work including liver function tests, alpha-fetoprotein
(AFP) and abdominal ultrasound every 6 months. Patients
at increased risk include Asian men >40, Asian women >50
and all patients with cirrhosis regardless of age (30). In
addition, patients should receive extra consideration for
screening if they meet any of the following criteria: patients
with a first degree relative with HCC, African patients,
patients co-infected with HIV or HCV and patients with
evidence of active disease (30). Stratifying those patients
with CHB at highest risk for HCC is still unclear and has
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led to multiple scoring models designed to assess this risk.
These include the individual prediction model (IPM), CUHCC score, GAG-HCC score, NGM1-HCC, NGM2HCC, REACH-B score and the PAGE-B score (31). While
the initial models were not fully validated, more recently
developed models have shown more promise and multiple
have now been validated and are currently in use (31).
The CAMD scoring system was created by Hsu
et al. to assess the risk of development of HCC in
patients with HBV undergoing treatment with antiviral
therapy (32). This score was created using a Taiwanese
cohort and validated by a Hong Kong cohort, the scoring
system uses readily available information (cirrhosis, age,
male sex and presence of type 2 diabetes mellitus) to stratify
patients into low, intermediate and high-risk groups (32).
Based on the results of this study, the authors concluded
that the low and high-risk groups had distinctly different
risks of developing HCC (32). The risk of HCC was so
small in the low-risk group, annual incidence of 0.3%, that
the need to adhere to current screening guidelines was
questioned but no formal recommendations were made (32).
The risk estimation for hepatocellular carcinoma in
chronic hepatitis B (REACH-B) score is another validated
scoring system used to predict risk of HCC in patients with
CHB without cirrhosis (33,34) Developed using a Chinese
cohort and validated in separate cohorts from Hong Kong
and South Korea, this score used age, sex, HBeAg status,
HBV DNA and alanine aminotransferase levels in patients
without cirrhosis to assess the risk of developing HCC
(33,34). Ultimately, the 17-point risk score was able to
reliably predict the likelihood of developing HCC at 3, 5
and 10 years (33,34). A revised version of REACH-B, which
incorporated HBsAg levels, has also been developed to
provide further clarification of high-risk groups (35).
While previous scoring systems focused mainly on
Asian population, the PAGE-B score was developed in
attempt to risk-stratify Caucasian patients with CHB being
treated with antiviral therapy (36). This scoring system
incorporates only three factors (age, gender and platelets)
and was developed using a derivation and validation group
in patients taking modern antiviral therapies (entecavir and
tenofovir) (36). A modified PAGE-B score has subsequently
been created to identify CHB at risk of developing HCC in
Asian populations (37). Overall, being able to predict which
patients with CHB are most likely to develop HCC allows
providers to focus surveillance on the groups at highest risk.
Although treating CHB does not completely eliminate
the risk of getting HCC, it does significantly lower the
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chance of developing it. A study published by Nguyen et al
found that treatment with tenofovir in patients with CHB,
with or without cirrhosis, decreased the risk of developing
HCC from 20.13% for the untreated group compared to
4.69% in the treated group over an 8-year period (38).
There are multiple treatment options for patients
with HBV who do develop HCC. These include ablation
(radiofrequency ablation or the injection of ethanol),
embolization (chemoembolization vs radioembolization),
radiation, resection and liver transplantation (30,39).
It has recently been demonstrated that patients treated
for HBV prior to partial liver resection have better
outcomes including lower incidence of microvascular
invasion and reduced risk of early cancer recurrence (40).
Immunotherapy and chemotherapy are the last line of
treatment as palliative measures for metastatic disease (30).
The specific type of treatment will depend on the size of
the tumor, whether there are one or multiple tumors, local
experience with the different modalities and the presence/
absence of widespread disease.
Criteria for treatment
Patients with CHB have higher rates of many liver-related
complications including cirrhosis and HCC. Due to the
stability of cccDNA, the eradication and cure of hepatitis B
is extremely difficult. This difficulty has led to a paradigm
shift in chronic hepatitis B treatment, from the goal of
eliminating the virus to suppressing viral replication. When
considering viral suppression, not all patient populations
have a shown long-term benefit, such as decreased liverrelated complications of CHB (10). Because of this careful
selection when considering treatment is important (10).
Thus, the decision to treat patients with CHB is critical as
treatment will ultimately lead to significant improvement of
health outcomes in those populations who meet criteria.
The three main criteria used to determine if a patient
should be treated for CHB are serum HBV DNA levels,
serum ALT levels and the severity of liver disease (10,12,13).
Other factors that should be considered are age, overall
health status, family history of HCC or cirrhosis and
extrahepatic manifestations of disease (10,12,13).
Currently, differentiating between immune-active and
immune-tolerant states of chronic hepatitis B has important
treatment implications, though this may change in the
future (Table 1) (10). Immune-active CHB is defined as
ALT levels ≥2 the upper limit of normal (ULN), defined as
>35 U/L for men and >25 U/L for women, or significant
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histological evidence of disease plus elevated HBV DNA
(above 2,000 IU/mL for HBeAg negative or above
20,000 IU/mL for HBeAG positive patients) (10). It is
worth noting that the indication for treatment is mostly
independent of HBeAg status (10,12,13).
Antiviral therapy is currently recommended for immuneactive CHB to reduce the risk of liver related complications
of the disease (10). Additionally, all patients with
decompensated or compensated cirrhosis who are HBsAgpositive should be treated regardless of HBV DNA level,
ALT level or HBeAG status (10). In contrast, treatment is
not recommended for patients with immune-tolerant CHB
as the risk of developing complications is thought to be
much lower in this population (10).
Other patients with CHB to consider treating include
HBsAg-positive pregnant women but only if the HBVDNA level is >200,000 IU/mL (10). Treatment is
recommended to decrease the risk of perinatal transmission,
especially because the risk of CHB is very high for infants
despite vaccination and hepatitis B immunoglobulin
(HBIG) (10). Patients with chronic HBV who plan to start
immunosuppression therapy for any reason should also be
treated to prevent a reactivation flare.
Prior studies have shown that patients with CHB who
have significantly elevated HBV DNA (>20,000 IU/mL)
are at increased risk for developing HCC and cirrhosis
regardless of ALT levels (15,41). Despite this, current
guidelines do not recommend treatment of immunetolerant patients with high HBV DNA levels (10,13). A
new study by Kim et al. demonstrated that this population
may actually benefit from receiving early treatment (42). In
this study, the authors found that immune-tolerant patients
who were not treated for CHB had a higher risk for HCC,
death and need for liver transplant compared to patients with
immune-active disease treated with antiviral therapy (42).
Moreover, in patients with mildly active disease (ALT
levels 1–2× the ULN), the risk of HCC, death and need for
liver transplant were increased even further (42). Based on
these results, the authors surmised that many occurrences
of HCC, transplantation and death could be avoided by
treatment of CHB during the immune-tolerant phase (42).
While current guidelines continue have not yet changed
based on this data, with more research on the topic the
guidelines may change in the future.
Adherence to treatment is as important as careful
selection of patients who meet criteria for treatment. A
recent 10-year longitudinal observational study by Shin et al
demonstrated this by showing that patients who were non-
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adherent to treatment had an increased risk of complications
from cirrhosis, HCC, and mortality when compared
with patients with adherence rates of 90% or higher (43).
Specifically, patients with adherence rates <90% had a
2.9 times higher rate of both cirrhotic complications and
HCC (43). These patients also had a significant increase in
liver-related (14.3-fold) and all-cause mortality (5-fold) (43).
Not surprisingly, patients with good adherence rate also had
a higher rate of virologic response, maintained virologic
response and had lower rates of virologic breakthrough (43).
Of note, patients who receive long-term treatment for
CHB have similar overall and liver-related survival rates to
those in the general population (except those with HCC)
over an 8-year follow up period (44). Patients who received
treatment also had improvement in histological findings
of fibrosis and reversal of early liver decompensation (36).
These findings again support the need for treating patients
with CHB.
Despite the mounting evidence of improved outcomes of
patients with CHB who receive treatment, global treatment
rates remain low (45). In 2016, only one in six patients
diagnosed with HBV worldwide received treatment (45).
This is somewhat surprising given the international market
price of the two most common HBV medications (tenofovir
and entecavir) has decreased significantly in recent years (45).
For example, the price of generic tenofovir declined 85%
from 2004 to 2016 (45).
Overall, treatment of patients with CHB is critical to
help control this disease. Knowing who to treat is a vital
aspect. Also, those who are treated should be monitored
closely for adherence. These habits will lead to better
outcomes and longer lives for patients living with this
disease.
Treatment options
The treatment for CHB has evolved dramatically over
the last 3 decades. The first known therapy for CHB was
interferon-α (IFN-α) that was introduced in the early
1990s (46). Interestingly, it is the only known medication
that can actively degrade cccDNA but the response rates
to treatment are low with less than 10% ever testing
negative for HBsAg and less than 50% demonstrating viral
suppression (10). Furthermore, the severity of adverse
side effects associated with IFN precluded the use of this
therapy for all populations (47). The paradigm shifts away
from complete elimination of the virus to suppression led to
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the introduction of nucleos(t)ide analog inhibitors (NAIs).
The introduction of Lamivudine (LAM) in 1998
presented an oral regimen that was highly effective at
suppressing viral load, which subsequently decreased liverrelated morbidity and mortality (48). Unfortunately, data
indicated that HBV would quickly develop resistance to
LAM after as little as 1 year of therapy (49). Indeed, in a
5-year study, the incidence of LAM resistance increased
from 23% at 1 year to 65% in 5 years (49). Moreover,
longer duration of therapy led to increased risk of resistance
development (49). Following the addition of LAM, several
other therapies have been developed but the current firstline medications have largely supplanted all other available
treatment options (10,13). This is primarily due to the high
genetic barrier for resistance development in HBV (48).
There are 3 current first-line treatment options:
entecavir (ETV), tenofovir disoproxil fumarate (TDF), and
tenofovir alafenamide fumarate (TAF). Since eradication
of HBV is not universally feasible with current therapies,
other endpoints are used to monitor efficacy of treatment
for CHB. These markers include normalization of
serum ALT, HBeAg seroconversion, and HBV DNA
suppression (10).
Entecavir (ETV)
Entecavir is a guanosine analog that leads to chain
termination when incorporated into HBV DNA during
replication (48). The effectiveness of ETV has been
demonstrated in both HBeAg-positive and negative
patients and has proven to have sustained long-term
benefits in liver-related morbidity and mortality outcomes
(50-52). The side effect profile of ETV is mostly
benign with the most concerning side effect being the
development of renal disease (53). While ETV does not
appear to cause renal failure, it may lower the GFR and
dose adjustment is required depending on degree of renal
disease (53). Development of resistance to ETV has been
documented and the risk of HBV resistance to ETV therapy
was noted to be 1.2% after 5 years of therapy (54). This
has led to the phrase ‘high-genetic barrier of resistance’
when describing ETV, as well as TAF/TDF. However,
in patients who are LAM-experienced the risk of HBV
resistance was noted to be 51% after 5 years as ETV is
a pyrimidine analog similar to LAM (54). Therefore, in
LAM-inexperienced patients, ETV can be considered
first-line therapy in patients (10).
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Tenofovir (TAF/TDF)

Nucleocapsid assembly inhibition

Tenofovir is an adenosine analog that, like ETV, leads
to chain termination during HBV replication (48).
Tenofovir disoproxil fumarate (TDF) was the first tenofovir
formulation available and was FDA-approved for use on
the basis of its efficacy when compared to a previously used
agent named adefovir (55-57). The effectiveness of TDF
is comparable to ETV, which is why either is acceptable as
first-line therapy for CHB (10). Unlike ETV, there are no
documented cases of resistance to TDF therapy (58). The
side effect profile for TDF is also relatively benign except a
small portion of patients who have developed drug-related
decreased bone density as well as renal toxicity (55,59).
Dosage adjustment is required in the setting of renal disease
(55,56). The increased risk of osteopenia and renal toxicity
led to the development of tenofovir alafenamide (TAF),
which is noted to have the same efficacy of TDF but has a
somewhat better safety profile (60).

The replication of HBV DNA occurs in nucleocapsids
that are assembled prior to replication (66). Therefore,
if the assembly of the nucelocapsid can be disrupted, the
replication of viral DNA can be stopped (66). To that
end, several compounds have been developed which are
in preclinical or clinical development that act by either
forming empty nucleocapsids which lack HBV DNA or
non-capsid polymers (66). Using cellular models, these
compounds have shown promising results in terms of
antiviral activity (67,68).

Future therapies
Although current therapies for CHB are effective in
suppressing the virus and causing normalization of ALT,
there is currently no cure for HBV. Additionally, all firstline therapies require indefinite or prolonged treatment.
Several novel therapies are under development that explore
a variety of different treatment targets.
HBV entry inhibitors
One potential target currently being studied is inhibiting
the entry of HBV particles into the hepatocyte. The viral
particle does this through binding of specific proteins with
the hepatocyte to gain entry (61,62). A compound has
been developed, myrcludex B, that may inhibit viral entry
by blocking the hepatocyte proteins required for HBV
binding (63). A phase 1b/2a study was conducted in 24
patients co-infected with HBV and hepatitis D virus (HDV)
which randomized patients to have either Myrcludex B,
pegylated interferon α (PEG-IFN), or both and found that
the use of myrcludex B with PEG-IFN was effective for
viral suppression after 24 weeks (64). While these results
are promising, the concern is that the drug acts on a bile
acid transporter and may affect the non-infectious related
function of the transport (64,65). In addition, this drug may
require PEG-IFN to be effective however new compounds
are being developed that may circumvent this issue (64,65).
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DNA editing technologies
The advent of DNA-editing technology has funneled
interest into development of a treatment that can specifically
inactivate, or even eradicate, cccDNA from hepatocytes
without damaging the hepatocyte chromosomes (66). The
use of clustered, regularly interspaced short palindromic
repeats (CRISPR)/CAS9 can edit the HBV cccDNA in a
Hepatitis B-infected cell line (69,70). The specifics on how
this can be translated into infected patients, as an efficient
delivery system to infected hepatocytes, has not yet been
developed and is still under investigation (66).
Conclusions
Treating CHB has become the next frontier in the treatment
of viral hepatitis after the highly effective antiviral cure
for hepatitis C has become readily available. CHB afflicts
millions worldwide and understanding the pathophysiology
and natural history of the disease has important screening
and treatment implications for the disease. Current
therapies are effective in suppressing the viral replication
and improving liver-related outcomes but no virological
cure has yet become available. New and exciting research in
the field holds promise in preventing viral replications and
hopefully can lead to a cure for this disease.
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